

2021

API LIST

Almelo Private Limited



For more details, please write to
enquiries@almelochem.com

<i>PRODUCT</i>	<i>QUALITY GRADE</i>	<i>STATUS</i>
Ranolazine	In-House/ USP PF 44(3)	US DMF Filed EU ASMF Filed China NMPA DMF Filed
Pregabalin	IP/ USP/ Ph. Eur/ BP/ In-House	US DMF Filed China NMPA DMF Filed CEP Granted JDMF Filed KDMF Filed ANVISA DMF Filed
Sugammadex Sodium	In-House	EU ASMF Filed
Dolutegravir Sodium	In-House	WHO DMF Under Compilation
Levocetirizine DI-HCL	USP/IP/In-House	Validation Completed
Empagliflozin	In-House	In-House DMF Available
Ziprasidone DI-HCL	USP/IP	In-House DMF Available
Doxazosin Mesylate	USP/BP/In-House	In-House DMF Available
Alfuzosin HCL	USP/Ph.Eur	In-House DMF Available
Cetirizine DI-HCL	USP/Ph.Eur/IP/BP	In-House DMF Available
Prazosin HCL	USP/EP	In-House DMF Available
Silodosin	In-House	In-House DMF Available
Darunavir Ethanolate	In-House	Under Validation
Ziprasidone Mesylate Trihydrate	Ph.Eur/In-House	Under Validation
Sitagliptin Phosphate Monohydrate	USP/ Ph.Eur/ IP	Under Validation
Oclacitinib Maleate [VET]	In-House	Tech Pack Ready
Azilsartan Base	In-House	Tech Pack Ready
Sitagliptin HCL	In-House	Tech Pack Ready

DEVELOPMENT PIPELINE:

PRODUCT	QUALITY GRADE	STATUS
Avibactam Sodium	In-House	Under Development
Azilsartan Medoxomil	In-House	Under Development
Bempedoic Acid	In-House	Under Development
Bilastine	In-House	Under Development
Candesartan Cilexetil	In-House	Under Development
Dabigatran Etxilate Mesylate	In-House	Under Development
Fosravuconazole	In-House	Under Development
Garenoxacin	In-House	Under Development
Pentosan Polysulfate Sodium	In-House	Under Development
Terazosin HCL	USP	Under Development

Manufacturing Site Compliance Status: ISO 9001: 2015; ISO 14001:2015; BS OSHAS 18001:2007; DCA; WHO GMP; EU GMP; EU Written Confirmation; Japanese AFM PMDA

USFDA; KFDA; Chinese NMPA, WHO Geneva – Schedule Shortly.

Contact Address: enquiries@almelochem.com

Website: www.almelochem.com

Note: Products protected by Patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk. Samples of products under patent can be supplied only for R&D purposes.